GENB financial statements
The full income statement, balance sheet, and cash-flow statement for Generate Biomedicines Inc. (GENB), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Income Statement | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Revenue | 6.31M | 7.22M | |
| 77.9M | 71.3M | ||
| Research & development | 64.3M | 57.8M | |
| Selling, general & administrative | 13.6M | 13.5M | |
| General & administrative | 13.6M | 13.5M | |
| Operating income | -71.6M | -64.1M | |
| Interest expense | 155K | 182K | |
| Interest & investment income | 4.63M | 2.91M | |
| Other non-operating income | 4.41M | 2.43M | |
| Pre-tax income | -67.2M | -61.7M | |
| Income tax | 53.0K | 28.0K | |
| -67.3M | -61.4M | ||
| Net income to non-controlling interest | 0.00 | -268K | |
| Net income to common | -67.3M | -69.2M | |
| -$0.52 | -$1.07 | ||
| EPS (basic) | -$0.52 | -$1.07 | |
| Weighted-avg shares (basic) | 128M | 64.9M | |
| Weighted-avg shares (diluted) | 128M | 64.9M | |
| Balance Sheet | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 470M | 535M | ||
| Cash & equivalents | 135M | 161M | |
| Short-term investments | 322M | 356M | |
| Cash & short-term investments | 457M | 517M | |
| Prepaid expenses | 12.8M | 18.7M | |
| 562M | 626M | ||
| Property, plant & equipment | 27.3M | 27.8M | |
| Operating lease right-of-use | 55.1M | 57.8M | |
| Other non-current assets | 9.06M | 4.75M | |
| 56.6M | 58.4M | ||
| Accounts payable | 5.65M | 7.62M | |
| Deferred revenue | 12.2M | 17.2M | |
| Current lease liability | 9.88M | 10.4M | |
| Other current liabilities | 2.52M | 2.42M | |
| Finance lease liability (current) | 3.74M | 3.88M | |
| 106M | 111M | ||
| Deferred revenue (non-current) | 0.00 | 1.24M | |
| Non-current lease liability | 47.6M | 49.1M | |
| Finance lease liability | 1.37M | 2.22M | |
| Other non-current liabilities | 0.00 | 0.00 | |
| 456M | 515M | ||
| Common stock | 128K | 128K | |
| Additional paid-in capital | 1.26B | 1.25B | |
| Retained earnings | -805M | -738M | |
| Accumulated other comprehensive income | -129K | 24.0K | |
| Non-controlling interest | 0.00 | 0.00 | |
| Total liabilities & equity | 562M | 626M | |
| Common shares issued | 128M | 128M | |
| Common shares outstanding | 128M | 128M | |
| Shares outstanding (cover) | 128M | 128M | |
| Cash Flow | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| -57.9M | -80.4M | ||
| Depreciation & amortization | 3.20M | 3.27M | |
| Share-based compensation | 8.24M | 6.39M | |
| Change in receivables | 0.00 | 0.00 | |
| Change in payables | -1.95M | 3.75M | |
| 33.3M | -260M | ||
| Capital expenditure | 933K | 3.78M | |
| Free cash flow | -58.9M | -84.2M | |
| Acquisitions | 0.00 | 0.00 | |
| -579K | 379M | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Net change in cash | -25.2M | 38.6M | |
| Valuation Ratios | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Market cap | 2.17B | 1.60B | |
| P/B | 4.7× | 3.1× | |
| Source filing | 10-Q | 10-Q |
About this data
Source: GENB’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all GENB filings on SEC EDGAR → Not investment advice.